Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

A new kind of pharma-telehealth partnership has come under scrutiny over concerns that such an arrangement could lead to inappropriate prescriptions and poor care.

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. | Eli Lilly is expanding its menu of ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Chinese Vice Premier He Lifeng met with top executives from Apple Inc. (NASDAQ:AAPL), Pfizer Inc. (NYSE:PFE), Mastercard Inc.

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Read Also: China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing ‘Will Continue To Improve The Business Environment’ Why Eli Lilly, Palo Alto Networks? According to ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...